Cannabis investors are keenly aware of the landscape and how it could play out for the industry.
Let's take a close look at Canopy Growth, GrowGeneration and cannabis REIT Innovative Industrial Properties.
In a few years, online gambling and legal cannabis will be allowed in more places than they won't be.
The bear case is still intact.
Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target.
This is a very healthy market and some consolidations and pullbacks would be advantageous for trading.
The available data don't paint a clear picture of the extent of the rebound in sales in different states.
Sometimes the best way to play a theme is with the 'pick and shovel' method.
Just as we saw with pot stocks, if you play shares strictly because they're going up, you're likely to get burnt.
Ayr Strategies is expanding in a contracting market.
The amended deal between the two cannabis companies is a doozy.
I continue to recommend a reduced long exposure on STZ.
Publicly traded cannabis companies are expected to take big write downs on assets, and here's why it matters.
Let's review the charts and indicators ahead of earnings.
As psychedelic medicines begin to become decriminalized, psilocybin seems to be leading the way in this category.
Fresh off IPO, company sees mushrooming opportunity in psilocybin.
There are huge problems now plaguing the industry, which was just beginning to recover from last year's oversupply issues.
TCNNF is a 'seed-to-sale' company that offers 155 products.
Only five companies went public during the first half of 2020 versus 13 in the first half of 2019.
Following widely reported lung injuries and bans, the products struggle to come back as concerns over Covid-19 burn on.
These names are displaying both technical and quantitative deterioration.
Don't be in a rush. The key to accumulating stocks in this environment is to move incrementally.
A fresh look at the budding hydroponic supplier.
While HRVSF has navigated through numerous changes and delivered solid revenue, litigation issues are piling up.
GRWG has no meaningful competition. The companies in the space are one-third the size and not competing on the same national scale.
Here are two tech-infused names to watch this year.
Many in the cannabis industry have been surmising that states will look to cannabis to plug any budget shortfalls.
Psychedelic companies hoping to capitalize on a surging interest in psilocybin treatments have been limited to one source for research grade psilocybin. Until now.
The big question is how does this action resolve itself?
Real Money tapped an industry expert to discuss the outlook for buying and selling of cannabis companies.